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Abstract
Prion diseases have been widely studied, but despite many great leaps in our knowledge
of prion and protein misfolding diseases in general, many gaps remain. One example is
the structural triggers or provocators of prion conversion found within the prion protein
(PrP) itself. While factors interacting on PrP can promote or dissuade conversion,
it is also evident that inherent properties of differing PrP (presumably especially
conformation) have an effect on the likelihood of prion conversion. Previous work
from our lab found that the substitution of histidine 95 with a tyrosine increased prion
conversion, while the same individual substitution at four other copper-binding histidines
of PrP had no effect on prion conversion propensity. Therefore, we focused on the role
of mutations at this amino acid of the mouse PrP (MoPrP), H95, to explore if this
increase in prion conversion is unique to the H95Y mutation and better understand
how mutations here affect conversion. In this original work, we perform an amino
acid scan at H95, replacing the histidine with every other common amino acid and
comparing the prion conversion propensity. The results are remarkable with the residues
with hydrophobic side chains increasing prion conversion by about 150% and residues
with electrically-charged side chains decreasing prion conversion by about 75%, both
compared to WT PrP. We continued and provide the first robust data that mutations on
the prion protein at residue 95 (specifically H95D, H95E, H95K and H95R) decrease the
propensity for cellular PrP (PrPC) to misfold into scrapie PrP (PrPSc), with transient
transfection of mutant proteins into ScN2a cells. We next biochemically characterize
PrP H95E and PrP H95Y, the most promising mutant for reducing and increasing
conversion, respectively, in N2aPrP−/− cells stably transfected with the mutant PrPs.
We conclude that PrP H95E and PrP H95Y are biochemically similar to PrP WT.
Also with these generated stable cell lines, we use immunofluorescence to study the
localization and trafficking of the mutant PrPs relative to organelle markers. The only
difference we observed was relative to the endosomal recycling compartments, with
PrP H95E co-localizing less compared to PrP WT and PrP H95Y co-localizing more
compared to PrP WT. This is in agreement with other work that links the endosomal
recycling compartments with prion conversion. More work is required to understand
what structural changes, if any, occur on the PrP H95E mutant and to understand if
this plays a role in conversion, similar to the work carried out on the PrP H95Y mutant.
At this point we conclude that the replacement of PrP H95 with electrically charged
side chains decreases the prion conversion propensity, and after a detailed study of PrP
H95E conclude that this is likely due to reduced co-localization with the endosomal
recycling compartments, but we cannot rule out the influence of structural changes
and would like to continue studies along this line.
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1 Chapter 1Introduction
Prion diseases have been widely studied, but despite many great leaps in our knowledge
of prion diseases and protein misfolding diseases in general, many gaps remain. One
example is the structural triggers or provocators of prion conversion found within the
prion protein (PrP) itself. While it is true that many factors interacting on/with PrP
can promote or dissuade conversion, it is also evident that inherent properties of PrP
(presumably especially conformation) have an effect on the likelihood of prion conversion.
To better understand this, we have focused on a single amino acid of the mouse PrP
(MoPrP): H95, which, amazingly, simply by its substitution with other single amino
acids can dramatically change the prion conversion propensity of PrP. In this original
work, which I present here, we provide the first robust data that the mutation PrP
H95E results in diminished prion conversion and link this to the mutated protein’s
diminished accumulation in the endosomal recycling compartment in vitro.
A note on terminology: many terms have been suggested in the literature to refer to
the prion protein, for simplicity in this dissertation I will use PrP to refer to the prion
protein in general, PrPC in reference specifically to the cellular prion protein and PrPSc
or prion to broadly refer to the misfolded form of the prion protein associated with
disease. Also, for the numbering of the prion protein I will use as my reference the
mouse Prnp codon numbering, which is -1 compared to human PRNP due to a single
amino acid deletion in the N-terminus (Gly54), unless indicated otherwise.
1.1 Prion Diseases
Incurable, irreversible, fatal, and rare: prion diseases are a group of neurodegenerative
disorders affecting humans and other mammals. Their uniqueness relies on a surprising
phenomena: the ability to infect and replicate without nucleic acids. It took decades
of research and head-scratching to alter the standard views shared by the scientific
community with respect to the characterization of infection, that nucleic acids are
necessary to replicate. While nucleic acids are commonly needed (in viral and bacterial
infections for example), prion diseases replicate using only the information stored in the
protein conformation [31].
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Prion diseases manifest as genetic, sporadic or infectious [15]. They include Creutzfeldt-
Jakob disease (CJD), Variant Creutzfeldt-Jakob Disease (vCJD), Gerstmann-Straussler-
Scheinker Syndrome and Fatal Familial Insomnia in humans; Bovine Spongiform En-
cephalopathy in cattle, Chronic Wasting Disease in cervids, and scrapie in sheep, to
name a few (for a more complete review see [8]). Classic neuropathological features
of prion disease are spongiform change, neuronal loss and gliosis (of astroglia and
microglia) [7]. Clinical symptoms and incubation times vary widely, but generally once
clinical symptoms; including most frequently motor dysfunction, cognitive impairment
and cerebellar dysfunction; appear disease progression is rapid, leading to death.
Premortem diagnosis is difficult and there is currently no standard clinical diagnostic
test. However, studies with real-time quaking-induced conversion (RT-QuIC), which
detects prions by amplifying them into amyloid fibrils, has shown promise as a tool for
diagnosis, especially from olfactory mucosal brushings [12]. All treatments to date have
failed to modify disease outcome [8].
Research in the prion field endeavours, ultimately, to find treatments for prion diseases, a
branch of infectious diseases whose mechanisms and effects have perplexed the scientific
community for decades on end. The understanding of the PrP structure, mainly how
changes in the primary structure of PrP affect the likelihood for prion conversion, is
a stepping stone toward this endeavour and encompasses some of the most exciting
venues in prion research. Why does a simple, at first sight, conformational change
produce such extreme and devastating effects in living organisms? The understanding
of the mechanisms involved will shed light in what has become an endless fight against
neurodegenerative diseases. A fight which will only be won by unveiling the long-sought-
after prion switch, critical for disease onset and propagation.
1.2 The prion protein (PrP)
PrP is highly conserved among mammals [9]. PrP is expressed in both the nervous
system and peripheral tissues, however its highest expression levels occur in neuronal
cells [13].
1.2.1 Cellular prion protein (PrPC) structure
Cellular prion protein (PrPC), refers to the physiological, native folded form of PrP.
PrPC is predominantly found attached via a Glycosylphosphatidylinositol (GPI) anchor
to the outer leaflet of the plasma membrane, exposed to the extracellular space. The
C-terminal of PrPC (127-231) is a structured, globular and largely α-helical, with three
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α-helices (α1, α2, α3) and two short β-strands (β1, β2). The N-terminal domain
(23-126) is intrinsically disordered and contains: two charged clusters (CC1 and CC2),
the octarepeat region (OR; 59-90), the non-octarepeat region (non-OR; 91-110) and
a hydrophobic domain (HD; 111-126). The N-terminal can bind copper (Cu2+) with
high affinity at four sites in the OR region and two sites in the adjacent non-OR region.
Additionally, a disulphide bridge and two N-glycosylation sites are found in the globular
domain (Figure 1.1) [69] [73].
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Figure 1.1: PrPC Structure (A) Schematic diagram of PrPC structure. The carbohydrate
moieties are shown in pink, the C-terminal GPI-anchor in green extending
into the cell membrane and the drawn residues in the N-terminal domain are
known to bind copper ions (blue spheres). (B) Organization of mouse PrP.
Unprocessed PrP includes the signal peptide (1-22), octarepeat region (OR;
59-90), non-octarepeat region (non-OR; 91-110), hydrophobic domain (HD;
111-126), one disulphide bond between cysteine residues (178-213), two
N-linked glycosylation sites (at residues 180 and 196), and a GPI-anchor
attached to the C-terminus of PrP replacing the GPI-anchor signal (residues
232 to 254). The six histidines of the N-terminal available to bind copper are
shown in blue circles. GPI: glycophosphatidylinositol. Modified from [10].
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1.2.2 Biogenesis of PrPC through the secretory pathway
PrPC is translated and undergoes several post-translational modifications on its way
to expression on the cell membrane. First, ribosomes began translation of Prnp
mRNA in the cytosol, until the signal peptide (1-22) directs it to be co-translationally
translocated to the endoplasmic reticulum (ER) [123]. Here, the remainder of the
protein is translated directly into the ER. During translation, N-linked oligosaccharide
chains can be added at neither, one, or two of the available asparagine residues, 180 and
196 (this corresponds to the non-, mono- or diglycosylated forms of PrP, respectively).
The N-linked oligosaccharide chains at this point are the high mannose type and are
sensitive to digestion by Endoglycosidase H (Endo H), therefore PrPC at this stage is
considered immature. The hydrophobic C-terminal α-helix, a GPI-signal peptide, is left
buried in the membrane of the ER after translation and the signal peptide is cleaved,
leaving 23-254. The GPI-signal peptide is also cleaved and replaced with a GPI anchor,
which stays inserted in the membrane, now leaving 23-231 [117] [118]. The oxidative
environment of the ER lumen allows for the formation of the disulphide bond between
cysteine residues 178 and 213 [122].
Next, PrPC is transported by vesicles to the Golgi. Here the N-linked oligosaccharide
chains are modified, resulting in diverse and complex-type chains containing sialic acid,
rendering them resistant to Endo H digestion, but still susceptible to digestion by
the Peptide:N-Glycosidase F (PNGase F) [124]. PrPC is now considered mature and
is transported to the cell surface by an exocytic vesicle. Here it remains anchored,
by the GPI, to the outer leaflet of the plasma membrane [119]. At the cell surface
PrPC associates with cholesterol- and glycosphingolipid-rich lipid rafts through its GPI
anchor [14].
1.2.3 PrP trafficking and processing
From the cell membrane, PrP can enter into the endocytic pathway. In neurons,
PrPC translocates out of lipid rafts into detergent-soluble regions where it undergoes
endocytosis in clathrin-dependent pathways. Copper binding to PrPC promotes its
endocytosis via the clathrin-dependent pathway [99] [83]. PrPC then enters early
endosomes and is sorted to the endosomal recycling compartment and returned to the
plasma membrane, the most common route for PrPC, or to late endosomes/lysosomes
for degradation [120] [121] (Figure 1.2).
Additionally in the endocytic compartments, a fraction of PrP is proteolytically cleaved
through PrP processing. Mature PrP proteolytic cleavage is termed α-, β- and possibly
a third type, γ-cleavage. PrP cleavage creates the PrP fragments: N1 and C1, N2
5
Figure 1.2: Schematic of the route commonly followed by PrP in the endocytic pathway.
and C2, and C3, respectively. Studies indicate that PrP cleavage may have important
physiological and pathological implications [20] [21] [22] [23], which we will discuss in
more detail in Section 1.3.2.3.
1.2.4 PrPC and copper binding
1.2.4.1 Copper and PrPC expression
First it was found that copper, when added extracellularly to in vitro neuronal cultures
significantly decreases PrPC mRNA, increases the release of PrPC into the culture
medium and decreases the total PrPC protein present in the cells [92]. Treatment
with cuprizone (CPZ), a well known selective copper chelator that does not affect cell
viability and cannot cross plasma membranes, completely restored PrPC mRNA and
protein expression. However, other studies found the opposite, that adding copper to
cell lines results in increased levels of PrPC expression [98] and that primary neurons
exposed to increased copper concentrations also upregulated PrP expression at both
the mRNA and protein levels (copper chelation, this time by bathocuprionedisulfate
(BCS), inhibited the increase of PrPC expression) [93].
1.2.4.2 Endocytosis of PrPC and copper uptake
PrPC predominantly localizes at synaptic membranes, especially presynaptically, where
copper is also highly localized [94]. It has been shown that PrPC expression influences
brain copper content. When PrPC is removed in Tg mice, referred to as PrP knockout
mice (PrP KO mice), these mice showed a synaptosomal copper decrease of more than
50% compared to WT mice [97] [95]. Copper also influences PrPC endocytosis, copper
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added to the medium of cultured neuroblastoma cells rapidly and reversibly stimulates
the endocytosis of PrPC from the cell surface [99]. Additionally, deletion of the one
of the copper-binding regions, the OR, stopped the endocytosis, indicating that this
region directs the internalization of PrPC in response to copper. Interestingly, a mutant
form of PrP with nine additional octarepeats, which is associated with familial prion
disease, was unable to participate in copper-mediated endocytosis [83]. These results
suggest a physiologically relevant role for PrPC binding with copper, where PrPC could
serve as a copper transport mechanism across the membrane or a type of copper buffer
at the synaptic cleft.
1.2.5 PrPC Function
The fact that PrPC is highly evolutionarily conserved among mammals suggests that it
carries out some beneficial physiological functions, or evolutionary selection would likely
have eliminated it. PrPC is expressed in many organs and tissues, with the highest levels
of expression being the central and peripheral nervous systems (CNS and PNS) [26].
Increasing evidence supports a central role for PrPC in neuroprotection. Proposed
PrPC functions include synaptic plasticity [74], cell signaling [76], neuronal growth and
differentiation [75], N-methyl-D-aspartate (NMDA) receptors modulation [77] [111] [79]
and brain metal homeostasis [80]. These latter two proposed functions directly involve
the ability of PrPC to bind divalent cations, primarily copper [81].
Gross phenotypes are not observed in PrP KO mice [27]. However, upon careful and
detailed studies structural and functional abnormalities in the PNS as well as structural
and functional abnormalities following the application of stressors in the CNS are
observed.
A plethora of phenotypes have been attributed to the PrP KO mice, but researchers
have realized that some of these were simply genetic artifacts of the underlying mouse
models [19]. Many experiments are being reassessed using new animal models created
with the latest advancements in gene editing technology, most notably, the strictly
co-isogenic C57BL/6 J-Prnp ZH3/ZH3 mice from the Aguzzi lab, which differ from
wild-type mice only by eight deleted nucleotides in the Prnp reading frame [27].
Many physiological roles of PrPC have been put forward, most of which focus on the
unstructured N-terminal as the primary site involved in the function. Proposed functions
for PrPC relevant to this work will be discussed. For an in-depth review see [19].
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1.2.5.1 The functional N-terminal of PrPC
PrPC can bind to divalent cations such as copper and zinc via the OR and non-OR
regions of the flexible N-terminal [51]. The PrPC N-terminal has been reported to
interact with a substantial number of different proteins and that these interactions
constitute a physiological function of PrPC. In this manner, PrPC has been implicated
in many cellular process [19]. However, it is important to keep in mind that these
interactions may also be a natural consequence of the unstructured conformation of
the N-terminal region of PrPC. Therefore, studies simply showing interaction, without
strong supporting evidence on functionality should be taken with a grain of salt as their
only scientific conclusion pertains to what basically amounts to chemical properties.
The N-terminal of PrPC (residues 23-126) is unstructured in solution [68], but it is
generally divided up into three regions of interest: the octarepeat (OR), the non-
octarepeat (non-OR) and the hydrophobic domain (HD).
The OR region, residues 59-90, is composed of four tandem repeats of eight amino
acids (PHGGGWGQ), with histidine as the primary residue involved in copper coor-
dination [65] [66]. This region can coordinate up to four copper ions, with distinct
coordination geometries and high affinity [70]. The OR is very well conserved, sug-
gesting a functionally significant role for the region [67]. Copper can also bind to PrP
outside of the OR region, in the neighboring non-OR region (residues 91-110), at H95
and H110 [71]. Next in line is the HD (residues 111-126), which has been reported to
play a role during prion conversion [72]. These latter two regions, spanning residues
91-126, also show a high degree of conservation among mammalian species [73].
1.2.5.2 N-methyl-D-aspartate receptor (NMDAR) modulation by PrP
Several studies have suggested PrPC involvement in synaptic mechanisms and protection
against neuronal excitotoxicity at the molecular level. Documented interaction of PrPC
with ion channels and metabotropic glutamate receptors may provide insights into
potential mechanisms.
We will look into more detail into the interaction of PrPC with the glutamate receptor and
ion channel, N-methyl-D-aspartate receptors (NMDAR). NMDAR are heterotetramers
composed of two GluN1 and two GluN2 subunits and mediate critical CNS functions,
though excessive NMDAR activity can cause neuronal damage [110]. PrPC was found to
inhibit NMDAR and prevent calcium influx, which in excess is excitotoxic, by association
with the GluN2D subunit of the receptor [111]. Hippocampal neurons isolated from
PrP KO mice exhibited enhanced and prolonged NMDAR-evoked currents, due to a
functional upregulation of NMDAR with GluN2D subunits and NMDAR overactivity
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resulted in an increase of neuronal excitability. These effects were rescued upon the
overexpression of exogenous PrPC and phenocopied by PrPC RNA interference. PrP KO
mice were also shown to have increased depressive-like behaviour [112] and a reduced
pain threshold [113], with both behaviours reversed by pharmacological inhibition of
NMDAR. These studies suggest a functional role for PrP that is linked to NMDAR
regulation in neurons, restraining overactivity, with behavioural consequences.
Work continued on PrP and NMDAR and it was found that the interaction between
PrPC and NMDAR is copper-dependent [114]. When copper is chelated from cultured
rodent hippocampal neurons a similar effect is seen as when PrPC is ablated, NMDAR
show non-desensitizing currents even at physiologically low glycine concentrations. This
suggests that PrPC interacts in a copper-dependent manner with the NMDAR, where
copper-bound PrPC acts to limit excessive NMDAR activity that could lead to neuronal
damage. This work was expanded upon by another group, who also showed that
PrPC and copper cooperatively inhibit NMDAR, adding that the precise mechanism is
S-nitrosylation, a post-translational protein modification resulting from the chemical
reaction of nitric oxide with cysteine residues, of NMDAR [115]. They found that
NMDAR S-nitrosylation was decreased in PrP KO compared to wild type (WT) mice
and that copper chelation decreased NMDAR S-nitrosylation in WT but not PrP KO
mice. They propose that PrPC-bound copper ions act as electron acceptors in the
reaction between nitric oxide and NMDAR cysteine thiols, thereby supporting NMDAR
S-Nitrosylation, which is neuroprotective to the cell by reducing NMDAR overactivation.
1.3 The pathological form of the prion protein
(PrPSc)
PrP scrapie (PrPSc) is the disease causing form of the prion protein. PrPSc has the
same amino acid sequence as PrPC, but its tertiary structure is altered. This change
in conformation by misfolding is termed conversion, a post-translational event where
PrPC misfolds into PrPSc. This conversion is followed by self-propagation, spreading,
and accumulation of PrPSc, often resulting in disease.
Evidence suggests that PrPC can convert into diverse self-propagating conformations
of PrPSc, each of which in turn can propagate its own tertiary structure often with
distinctive biochemical and histopathological signatures [16]. This phenomena is termed
prion strains [17]. PrPSc is classically defined as detergent insoluble and protease
resistant [18], but it has now been well documented that prion infectivity can occur
even in strains that are sensitive to protease digestion [136] [137] [138].
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1.3.1 The protein-only hypothesis
Central to the prion field is the protein-only hypothesis. This states that the main
(and perhaps the sole) infectious agent of prion diseases is a misfolded protein, which
carries the information in its tertiary structure [32] [31]. Evidence collected to date
overwhelmingly supports the protein-only hypothesis. Critical landmarks are discussed
briefly in this section (for a detailed review see [33]).
Some of the first evidence supporting this hypothesis was the fact that PrP KO mice
are completely resistant to prion disease. PrP KO mice are incapable of propagating
PrPSc and do not become ill. So, it was shown that PrP is required for prion replication
and disease progression [116].
The absolute evidence for the protein-only hypothesis was the production of infectious
material from pure WT PrP. To this aim in 2004, bacterially expressed recombinant prion
protein (rPrP) was induced to misfold and aggregate in vitro, then injected into Tg mice
overexpressing PrP [34]. These mice succumbed to a transmissible neurodegenerative
disease with a long incubation period. Another group achieved the same results after
serial passages using another method to misfold and aggregate rPrP, but importantly in
WT animals (this time Syrian hamsters) [35]. These, and numerous other experiments
to date, notably using PMCA, provide extremely strong evidence for the prion protein
as the main infectious component of prion disease. However, despite infection achieved
in these cases, there was an unusually long incubation period and often an imperfect
attack rate [36]. Then, de novo generation of bona fide infectious prions in vitro by
PMCA that cause classic prion disease in WT hamsters was reported, where mixing rPrP
with phospholipids and RNA was the crucial step to achieve increased infectivity [37]. It
seems that efficient PrPC conversion to highly infectious PrPSc is aided by the presence
of host-encoded molecules, but it is not obligatory for the production of infectious
PrPSc [33].
All in all, the numerous experiments producing synthetic infectious prions in vitro
by various methods support the protein-only hypothesis of prions. Moreover, the
research lines proposing that several other proteins transmit biological information in
a prion-like manner, has reinforced the prion hypothesis. To name a few: in humans
many neurodegenerative diseases involve self-replicating proteins, referred to as protein
misfolding disorders (PMD), amyloid-β [39], α-synuclein [40], tau protein [38] (studies
suggesting the existence of distinct strains of these proteins, though without infectivity,
has also strengthened the prion hypothesis [43] [43]); and in yeast several prion-like
proteins carrying out functional biological roles such as new metabolic phenotypes have
been studied [41]. The protein-only phenomenon therefore potentially has widespread
implications.
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1.3.2 PrPSc and prion disease
1.3.2.1 PrPSc structure
Common structural features shared among PrPSc include an increase in the proportion
of β-sheet motifs, the ability to form aggregates, insolubility and often resistance to
proteinase digestion. In contrast, PrPC is soluble, low in β-sheet content and highly
susceptible to proteinase digestion [139].
PrPSc that is resistant to proteinase digestion can be detected by proteinase K (PK)
digestion, resulting in the N-terminal truncation leaving a PK-resistant core of about
142 amino acids, referred to as PrP27-30, in reference to its apparent mass of 27-30
kDa after electrophoresis. Not all PrPSc of prion diseases is resistant to protease
digestion [56]. The secondary structure can also be used to distinguish between PrPC
and PrPSc. Fourier Transform Infrared Spectroscopy (FTIR) and circular dichroism
(CD) studies have shown that unlike PrPC, which is predominantly α-helix (47% α-helix
and only 3% β-sheet), PrPSc is β-sheet enriched (43% β-sheet and 30% α-helix) [57].
The most recent studies on PrPSc structure using X-ray fiber diffraction [59] and electron
cryomicroscopy [58], point to a four-rung β-solenoid structure as a key feature for
the architecture of GPI-anchorless PrP 27-30 mammalian prions. This puts important
restrictions on the templating mechanisms involved and future studies will undoubtedly
shed more light on this area.
1.3.2.2 PrPSc conversion
Two main models have been proposed for the PrPC to PrPSc conversion process. The
”template directed-refolding model" proposes a heterodimeric interaction between PrPC
and PrPSc monomers, where PrPC overcomes the kinetic barrier and forms a new PrPSc
molecule. This interaction then dissolves and the two monomers of PrPSc are released,
each of which can bind to and convert other PrPC substrate [61] [62]. However, this
model is inconsistent with mathematical models of prion infectivity [125] [126]. Instead,
these models indicate that small oligomers would act as the most infectious prion units.
Studies support a minimum infectious unit of at least 5 PrP units, with the highest
infectivity in the 14-28 monomer range [126] [127]. This is in support of the ”nucleation-
dependant polymerization model", which proposes that PrPC and PrPSc monomers
are in a reversible thermodynamic equilibrium that strongly favors PrPC. However, if
the critical event of a primary nucleation event of an oligomeric PrPSc seed is able
to form, this structure is stable and can be infectious [63] [64]. The seed promotes
the self-templated conversion of soluble monomer PrPC at the ends of the oligomer
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seed, growing into a fibril [128]. The number of templating surfaces (i.e. the free ends
of the fibrils) is a limiting factor for the rate of conversion and consequently disease
progression. More templating sites are thought to be produced by secondary nucleation
processes, such as fragmentation [60].
PrP can be converted in vitro into oligomers and fibrils fairly easily. However, these
oligomers are often not toxic to cells, and even more challenging has been to produce
in vitro oligomers with infectivity titers seen in bona fide prions [44]. This and other
work, points to a disconnect between prion replication, toxicity and infectivity. For
example, PrP KO cells show no signs of toxicity even when bona fide prions accumulate
at high levels [45]. In this experiment, PrPC-expressing neural tissue grafted into PrP
KO brains exhibit scrapie pathology, but not the neighboring PrP KO tissue despite
the presence scrapie fibrils and plaques.
Another process to consider is cell-to-cell spread of prions. Large cargo classically enters
into cells by receptor-mediated endocytosis [46]. PrPC can undergo clathrin-mediated
endocytosis to early endosomes and is then sorted to endosomal recycling compartment,
which reroute PrPC back to the plasma membrane, or to late endosomes/lysosomes
for degradation. It is difficult to distinguish the exact compartments in which prion
replication occurs due mainly to the difficulty discerning PrPC from PrPSc in situ,
however many studies suggest that it occurs throughout the endocytic pathway [47] [49]
and/or at the plasma membrane [48].
Specifically within the endocytic pathway, the endosomal recycling compartment (ERC)
was found to be important for prion conversion [129]. Here the levels of PrPSc
generated in chronically infected neuronal cell lines were analyzed under conditions
where intracellular trafficking was selectively impaired. When PrP was blocked from
exiting the early endosomes, PrPSc levels were diminished, indicating that the sorting
from the early endosomes to subsequent compartments was essential for efficient prion
conversion. PrP can be trafficked from early endosomes to late endosomes or to the
ERC. Decreasing the number of late endosomes did not diminish PrPSc formation.
However, when PrP sorting from early endosomes to the ERC is specifically impaired,
PrPSc levels are drastically reduced. Furthermore, when PrP exit from the ERC is
impaired, PrPSc levels increase. This sets forth firm evidence that PrP accumulation
in the ERC promotes PrPSc production. Additionally, another study of the subcellular
distribution of PrPSc in scrapie-infected mouse hippocampal sections found a large
increase of PrPSc in the endosomal recycling compartments, also suggesting this as a
possible conversion site [130].
Surprisingly, PrPSc is still formed and internalized in cells when the dynamin/clathrin-
dependent endocytosis and macropinocytosis pathways are inhibited [50]. This suggests
these pathways are either not involved in PrPSc formation and internalization or that
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the process can occur through multiple pathways. Prion conversion is also diminished
by the disruption of lipid raft integrity, where PrPC associates at the cell membrane.
1.3.2.3 PrP cleavage role in prion disease
While PrP is cycling through the endocytic compartments it can be proteolytically
cleaved. The type of cleavage PrP undergoes, if any, impacts the ability of the resulting
fragments to participate in subsequent conversion events (Figure 1.3).
Figure 1.3: Schematic diagram of PrP processing. Modified from [11].
First we will look in more detail at α-cleavage. The membrane-anchored C1 fragment,
a product of α-cleavage between residues 110/111 or 111/112, is the major proteolytic
fragment of PrPC [131]. α-cleavage divides PrP right between the non-OR and
hydrophobic domain regions, a key area for prion conversion. Indeed, it has been
shown [24] that transgenic (Tg) mice expressing only the C1 fragment of PrP (PrP(∆23-
111)), termed Tg(C1), show no spontaneous disease and these mice, when inoculated
with scrapie prions do not accumulate PrPSc nor succumb to prion disease. This strongly
suggests that C1 cannot convert into PrPSc. If Tg(C1) mice co-express C1 and WT
PrP, they do get sick after scrapie prion inoculation, but at a much later date than
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WT mice. The authors conclude that the C1 fragment acts as a dominant-negative
inhibitor of PrPSc formation.
Other studies show that Tg mice lacking the α-cleavage site of PrP have spontaneous
neurodegeneration, though pathologically distinct from prion diseases (for a review
see [25]). This suggests that the production of the C1 and N1 fragment play an
important role in the brain apart from resisting PrPSc conversion.
β-cleavage occurs upstream of the α-cleavage site at roughly the end of the OR region
(∼residue 90), producing the N2 and C2 fragments [131]. Under physiological conditions
β-cleavage occurs at low levels compared to α-cleavage. However, during prion disease
β-cleavage is more prevalent, with C2 fragments found at high levels in the brains of
CJD patients [22]. Digestion by proteinase K (PK) results in a fragment comparable to
C2 and PrPSc processed by PK or β-cleavage retains its infectivity; importantly, in both
cases the non-OR and hydrophobic domain region remains intact. This was also seen
in vivo with Tg mice expressing an equivalent to the C2 fragment (∆32-80) had no
spontaneous phenotype, but were susceptible to prion infection with incubation times
similar to mice expressing WT PrP [84].
From studies on α- and β-cleavage of PrP, a necessity for prion conversion of PrP
is an intact non-OR and hydrophobic domain regions. This region is destroyed by
α-cleavage and the resulting C1 fragments are resistant to conversion into PrPSc. In
contrast, β-cleavage (and similarly PK digestion) leaves this non-OR, hydrophobic
domain region intact and will convert into PrPSc. These key regions, residues 90-126,
of PrP conversion have important implications for furthering our understanding of the
conversion process.
1.3.2.4 Deletions and insertions of the N-terminal and disease
In vivo studies also have shown that residues 90-126 are involved in prion generation
and maintaining physiological PrPC function(s). Deletion of only residues within the
OR region (PrP∆C; ∆32-93), results in mice that do not display any pathological
phenotype [90] and are susceptible to prion infection, but with long incubation times
[105]. Extended deletions, however, which include the OR, non-OR and HD (PrP∆E,
∆32-121; PrP∆F, ∆32-134) induce pathological lesions and result in death at 3-4
months [88]. The expression of PrP with deletions only of the non-OR and HD
(PrP∆CD; ∆94-134) induces a rapidly progressive, lethal phenotype with extensive
central and peripheral myelin degeneration. Finally, a PrP variant lacking only 8 residues
(PrP∆pHC; ∆114-121), which is a large segment of the HD, was innocuous. Another
group also found that mice expressing PrP ∆105-125 (deleting one of the two non-OR
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copper binding sites and the entire HD), develop a severe neurodegenerative illness
that was lethal within 1 week after birth [89].
Naturally occurring missense mutations clustered in the non-OR region and within the
palindromic motif (P102L, P105L, G114V and A117V, human numbering) result in
GSS syndrome [140]. GSS syndrome is characterized by PrPSc amyloid plaque deposits
in the brain. These PrPSc-inducing mutations support the idea of the non-OR as a key
influencer of PrPC function and prion conversion.
1.3.2.5 Large population analysis of the prion protein gene and the
identification of a spontaneous PrP H96Y mutation in a patient
A large set of human genomic data has been studied to assess the risk of prion disease
in relation to variants in the prion protein gene (PRNP) [28]. The results challenge
many missense PRNP variants that have been reported as pathogenic in the literature.
Most are likely benign PRNP variants falsely assigned as pathogenic, but some do
confer disease susceptibility but with vastly ranging penetrance. Interestingly, three
heterozygous loss-of-function variants were identified in healthy older individuals. So
it seems heterozygous loss of PRNP in humans is tolerated and could represent an
avenue for prion disease therapy. Most interestingly for our current work, they list a
rare PRNP variant, H96Y (human numbering, mouse numbering equivalent: H95Y), as
a probable prion disease case from Spain [28].
1.3.2.6 Prion diseases and copper
Copper’s effect on the prion protein, function and possible link with prion diseases
includes many contradicting studies have been reported concerning the involvement of
copper in prion diseases, making it very difficult to understand the true relationship
between copper and PrP. It is likely that these contradictions arise because of the
complicated nature of copper and PrP. Or an intricate balance where differences of the
cell or animal model and/or experimental methods, even small, could propagate to a
large differences in the final outcome.
In vivo studies reported that the addition of dietary copper to scrapie-infected animals
significantly delayed prion disease onset [103] [104]. Inconsistently, other in vivo
studies reported the opposite. One early study found that cuprizone, a copper chelator,
could delay or prevent terminal illness in scrapie-infected mice, though with very low
inoculation titers and low reproducibility [100]. Another study using D-(-)-penicillamine
(D-PEN) as a copper chelator, also found delayed disease onset in scrapie-infected
mice [109]. Of course, these in vivo studies involve changing copper homeostasis, a
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delicate balance, on a whole-animal level and it may simply be that copper influence
on PrPC and PrPSc is too intricate to be reproducibly studied in such broad-stroke
experiments.
Addition of copper inhibits both the conversion of PrPC to PrPSc in PMCA [101]
and the formation of fibrils of recombinant PrP in the amyloid seeding assay (ASA)
[102]. In transgenic mice studies, mice expressing PrP lacking the OR region, and
therefore partially lacking copper binding ability, have prolonged incubation times after
scrapie inoculation, even when this mutant PrP is overexpressed [105]. However, both
insertions [106] and deletions [107] [108] of the copper-binding OR result in human
prion disease.
The non-OR copper-binding region has been studied in more detail as of late since
it lies next to the HD. The HD, which importantly contains the palindromic motif
sequence AGAAAAGA, has recently been suggested to be involved in early structural
changes of prion conversion [85]. In fact, studies have found that a change in copper
coordination in the non-OR region induces structural changes that extend into this
neighboring hydrophobic region. However, studies disagree on whether copper binding
to PrP increases or decreases the likelihood of PrP to generate a β-sheet conformation,
which is widely interpreted as the first step to PrPSc formation. One study found that
when Cu ions are bound to PrP 90-126 (which exclusively includes the non-OR and
HD), the native fold of PrPC is destabilized and a β-sheet-like transition is observed [86].
Another study on the same region of PrP finds that when copper binds only to the
H110 site, β-sheet formation is reduced compared to the apo-peptide [87].
1.3.2.6.1 Disruption of copper binding at PrP H95Y promotes prion conver-
sion
Studies from our lab individually mutated five of the copper binding histidines from the
OR and non-OR to tyrosines (a conservative mutation that removes the physiological
copper binding ability). By analyzing the conversion susceptibility from PrPC to PrPSc
in vitro, they uncovered that only the mutation in the Non-OR region, H95Y, resulted
in a significant increase in prion conversion propensity [73]. When copper is depleted
from the medium by CPZ, conversion is increased in WT PrP compared to WT PrP
with unaltered copper levels. Interestingly, the conversion propensity of PrP H95Y
does not change when copper is chelated, though levels are still elevated compared
to WT PrP with or without CPZ addition. This indicates that while copper depletion
increases the likelihood for WT PrP to convert into PrPSc, the same is not true for
PrP H95Y. It is possible that the PrP H95Y mutant already converts to PrPSc at a
fast rate and lower copper concentrations have no appreciable effect. Or since the PrP
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H95Y mutant already cannot bind copper at the H95Y site, whereas the WT PrP likely
loses copper binding at H95 when copper is chelated, this copper binding at H95 is the
key interaction for PrP to resist conversion into PrPSc. In the amyloid seeding assay,
they used PTA-isolated PrPSc seed from ScN2a cells transiently expressing PrP H95Y
mutant to seed the conversion of recombinant full-length WT MoPrP. The addition of
the H95Y-PrPSc seed significantly promoted MoPrP fibrillization reactions at both pH
5.5 and 7.0, with shorter lag-phases than the control WT-PrPSc seed [73].
Using immunofluorescence, they studied the co-localization of PrP H95Y with the
3F4-tag transiently transfected into N2a cells. They found that the PrP H95Y mutant
colocalized with organelle markers: EEA1 (early endosomes), Tfn (endosomal recycling
compartment), M6PR (late endosome) and LAMP2 (lysosome marker). This suggests
that the PrP H95Y mutant predominantly accumulates in the acidic compartments [73].
However, these results would be strengthened using stably transfected cell lines and a
colocalization analysis.
1.3.2.6.2 The Non-OR region of the H95Y mutant is less structured in acidic
environments than WT PrP
Our lab used X-ray absorption spectroscopy to study the non-OR copper coordination
of human PrPC constructs: WT PrP and mutant PrP containing the pathological
mutations P102L, Q212P (both indicated in the familial prion disease GSS) and most
interestingly for this current work, H95Y. Firstly, they showed that in WT PrP pH
modified the non-OR copper coordination. At pH 7 copper is coordinated by H110
alone, but at pH 5.5 copper is anchored to both H95 and H110 in WT PrP [73]. In
contrast, in the PrP H95Y mutant (and incidentally, the other two mutants studied as
well), pH did not modify the non-OR copper coordination. The mutants have the same
copper coordination at pH 7 as WT PrP, but at pH 5.5 they lose the ability to anchor
copper at both sites and the metal can only coordinate at H110.
This, along with the in vitro work discussed earlier, provides biological and structural
evidence that the non-OR region may be critical for prion conversion. It has long been
suspected that the unique microenvironments of acidic compartments could act as the
cellular site for prion conversion. It was found that WT PrP participates in additional,
stabilizing copper coordination in such acidic conditions, while mutants that are unable
to participate in the double coordination of copper at H95 and H110 are less stable in
such environments and tend to misfold to PrPSc [73].
Thereby they conclude that when PrPC is only able to coordinate copper with one
histidine in the non-OR, it is susceptible to conversion to PrPSc in acidic conditions,
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proposing that the non-OR ”may act as the long-sought-after prion switch, critical for
disease onset and propagation" [73].
1.3.2.6.3 Spontaneous disease in transgenic mice expressing MoPrP H95Y
Tg mice expressing MoPrP H95Y (Tg H95Y) spontaneously develop prion disease,
presenting with neurological symptoms and reduced survival times compared to FVB
WT mice (unpublished data Legname Lab). Tg mice highly overexpressing PrP H95Y
6X, have short lifespans when inoculated with scrapie: those with a WT PrP+/+
background survived 108±19 days and those on WT PrP−/− background even shorter
at 96±6 days.
1.4 Aim of the study
This work seeks to shed light on one of the key events of prion disease, the conversion
from PrPC into PrPSc. The mechanism responsible for this event is still unknown. We
have approached this problem by systematically mutating the histidines of the OR and
non-OR regions of the N-terminal, hypothesizing that the loss of interaction between
copper and histidine may change the conversion propensity of PrPC. One histidine
from the non-OR region did cause a change of the prion conversion propensity, H95,
and we looked into this residue more closely, performing a amino acid scan at H95,
replacing histidine with every other common amino acid. Prion conversion propensity
was tested with the prion conversion assay, where exogenous 3F4-tagged PrP containing
our mutant of interest was transiently expressed in ScN2a cells, then analyzed by PK
digestion for PrPSc presence.
The resulting amino acid scan revealed a large range of prion conversion propensity
depending on the substituted residue. My work was further focused to better understand
the results of this preliminary scan, centering on the residues that decreased prion
conversion propensity (PrP H95D, H95E, H95K, H95R) and confirming previous work
indicating that the residue PrP H95Y increases prion conversion propensity. Our work
aims to reproduce the preliminary findings of the amino acid scan, to investigate the
involvement of copper chelation on prion conversion with relation to these mutants, to
biochemically analyze and to study the localization and trafficking of PrP H95E and
PrP H95Y. We anticipate that this work, combined with previous work from our lab,
will further our understanding of PrPSc formation.
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2 Chapter 2Materials and Methods
2.1 Plasmid Construction
2.1.1 Cloning of MoPrP mutants for cell transfection and
protein production
The mutations were inserted into pcDNA::MoPrP(1-254)WT, for the generation of
stable cell lines, pcDNA::MoPrP(1-254)WT3F4, for transient transfection in ScN2a cells,
or pET::MoPrP(23-231), for protein production, with the QuikChange mutagenesis kit
(Agilent Technologies) according to manufacturer’s instructions. Primers were designed
using the Primer Blast (NCBI) and QuikChange Primer Design (Agilent Technologies)
(Table 2.1). PCR parameters were as follows: melting temperature: 95◦C for 30 sec;
annealing temperature: 55◦C for 45 sec; extension temperature: 68◦C for 5 min. These
three steps were cycled 16 times. Strand extension was completed at 72◦C for 5 min and
reactions cooled to 4◦C. 10 ng of template DNA and 2.5 U PfuUltra DNA polymerase
was used in each reaction. PCR products were digested by DpnI (1 µL per 20 µL
PCR reaction for 1 hour at 37◦C) prior to transformation into competent DH5α cells.
Bacterial clones containing the plasmid (selected by ampicillin resistance) were cultured
O/N. Plasmid DNA was purified using the QIAprep Miniprep Kit (Qiagen). All the
constructs were verified by sequencing.
The pET11a expressing the full length MoPrP(23-231) was kindly provided by the
group of Prof. Jesus Requena (Universidade de Santiago de Compostela, Spain).
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Primer Sequence
H95D-Forward CAAGGAGGGGGTACCGACAATCAGTGGAACAAGC
H95D-Reverse GCTTGTTCCACTGATTGTCGGTACCCCCTCCTTG
H95E-Forward CAAGGAGGGGGTACCGAGAATCAGTGGAACAAGC
H95E-Reverse GCTTGTTCCACTGATTCTCGGTACCCCCTCCTTG
H95K-Forward CAAGGAGGGGGTACCAAGAATCAGTGGAACAAGC
H95K-Reverse GCTTGTTCCACTGATTCTTGGTACCCCCTCCTTG
H95R-Forward CAAGGAGGGGGTACCAGGAATCAGTGGAACAAGC
H95R-Reverse GCTTGTTCCACTGATTCCTGGTACCCCCTCCTTG
H95Y-Forward CAAGGAGGGGGTACCTATAATCAGTGGAACAAGC
H95Y-Reverse GCTTGTTCCACTGATTATAGGTACCCCCTCCTTG
Table 2.1: Primers used for MoPrP mutagenesis at H95
2.1.2 Cloning of full-length MoPrP H95E plasmid for Tg mice
construction
The pJB1:: MoPrP(1-254)H95E was amplified from pcDNA::MoPrP(1-254)H95E by
PCR using these primers:
- 5’Bsi-MoPrP: 5’-CCT AGT GGT ACC TCG TAC GCA GTC ATC ATG GCG AAC
CTT GGC TAC TGG-3’
- 3’Fse-MoPrP: 5’-CGC TCA CAA TCG CGG CCG GCC TCA TCC CAC GAT CAG
GAA GAT GAG G-3’
The PCR products were then ligated into pJB1 (modified vector from MoPrP.Xho
vector [5], in which BsiWI and FseI sites replaced the XhoI site) using the BsiWI and
FseI restriction sites. The PCR were performed using the Phusion DNA polymerase
(New England Biolab) according to manufacturer’s instructions. Plasmid DNA was
purified using the QIAprep Miniprep Kit (Qiagen). All the constructs were verified by
sequencing.
The pJB1 was kindly provided by the group of Prof. Glenn Telling (Colorado State
University, USA).
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2.2 Cell Cultures
2.2.1 Cell lines
• N2a mouse neuroblastoma cells were purchased from the American Type Tissue
Collection (ATCC CCL131).
• N2aPrP−/− cells [6] were kindly provided by the group of Dr. Gerold Schmitt-
Ulms (University of Toronto, Canada).
• ScN2a cells are N2a cells chronically infected with the Rocky Mountain Laboratory
(RML) prion strain.
2.2.2 Cell growth
N2a, N2aPrP−/− and ScN2a cells were cultured in minimal essential medium with
Earle’s salts (EMEM, Invitrogen) supplemented with 10% heat-inactivated fetal calf
serum, 1% nonessential amino acids and 1% penicillin-streptomycin in a humidified
atmosphere of 5% CO2 at 37◦C. Complete medium was changed 2-3 times weekly. All
cell culture work was carried out with strict aseptic technique. When cells reached
80-90% confluence they were harvested, sub-cultured or cryopreserved.
2.2.3 Cell harvesting
Cells were harvested from 10 cm cell plates in 400 µL cold lysis buffer (10 mM Tris
HCl pH 8.0, 150 mM NaCl, 0.5% Nonidet P-40 substitute, 0.5% sodium deoxycholate).
Cell debris was removed by centrifugation at 2600 rpm for 10 min at 4◦C in a bench
microcentrifuge (Eppendorf). An aliquot was taken for total protein quantification by
bicinchoninic acid (BCA) assay kit (Pierce) and the remaining supernatant was stored
at -20◦C until use.
2.2.4 Cell transfection
Cell transfections were performed using Effectene transfection reagent (Qiagen) following
the manufacturer’s guidelines. For transient transfections cell lysates were collected
72 hours post-transfection for further analysis. For stable transfections, 24 hours after
transfection, cells were cultured in the selective medium, comprised of complete medium
additionally supplemented with 0.3 mg/mL Geneticin (Invitrogen) (optimal Geneticin
concentration for this cell line, N2aPrP−/−, was determined by a dose response curve).
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The selective medium was changed every 3-4 days for about five days when most
Geneticin-sensitive cells had died. After that, individual cells were isolated in 96-well
plates by limiting dilution. Clones were expanded from individual cells, harvested for
Western Blot analysis of PrP expression levels and cryopreserved for subsequent use.
Stably transfected cell lines were maintained in complete medium supplemented with
0.3 mg/mL Geneticin (unless specified otherwise).
2.2.5 Cuprizone (CPZ) treatment
ScN2a cells were transiently transfected with mutant MoPrP (see Section 2.2.4). After
24 hours the medium was replaced with complete medium supplemented with 10µM
CPZ in 50% ethanol. Controls were cultured with an equal amount of 50% ethanol.
Cell lysates were collected after 48 hours of CPZ treatment.
2.2.6 Cell viability
To check cell viability of ScN2a cells transiently transfected with plasmids, cells were
seeded in a 96-well tissue culture plate one day before transfection and then transiently
transfected with MoPrP constructs. Seventy-two hours after the transfection the MTT
assay was performed. To check the viability of stably transfected cell lines, cells were
seeded in a 96-well tissue culture plate, cultured for 48 hours and the MTT assay was
carried out.
The MTT assay was performed as follows: the medium was removed and the cells were
incubated with 200 µL of MTT (Sigma) working solution (5 mg/mL of MTT in sterile
PBS 1X) for 4 h at 37◦C. Cell viability was assessed by the conversion of MTT (yellow)
to a formazan product (purple). The solution was removed and formazan products
were dissolved by adding 200 µL of DMSO to each well. The optical density was read
at 570 nm and the background subtracted at 690 nm using a VersaMax plate reader
(Molecular Device). Each assay was performed in duplication of 5 wells.
2.3 Protein Detection
2.3.1 SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
Protein loading buffer 2X (LB; 10% glycerol, 50 mM Tris HCl pH 6.8, 2% SDS, 4M
Urea, bromophenol blue and 0.2M DTT added fresh) was added to samples containing
a determined amount of total protein, ascertained by BCA. Samples were then boiled at
22
100◦C for 5 min. Then samples were spun down before loading onto 12% Tris-Glycine
gels. Gels were electrophoresed for 150 min at 100 V (or until the dye front ran off the
end of the gel). PageRuler Prestained Protein Ladder (Thermo Scientific) was used as
a molecular weight marker.
2.3.2 Coomassie staining of gels
After electrophoresis, to visualize proteins directly on the gel, gels were stained in
Coomassie ProBlue Safe Stain (Giotto Biotech) according to manufacturer’s directions,
repeating the final rinse until the protein bands were clearly visible.
2.3.3 Western blot
After electrophoresis, protein was transferred onto Immobilon PVDF membranes (Mil-
lipore) at 250 mA for 180 min or 30V overnight by wet transfer in Criterion Blotter
(Bio-Rad). A Ponceau S Staining Solution (0.1%(w/v) Ponceau S in 5%(v/v) acetic
acid) was applied to membranes to ensure efficiency of transfer, then rinsed away
completely with distilled water. Membranes were then blocked with 5% nonfat milk
powder in TBS-T (0.05% Tween), incubated with 1:1000 anti-PrP 3F4 antibody
(epitope: human specific M109-M112) and/or 1:1500 anti-PrP W226 antibody (epi-
tope: W144-N152), then incubated with the HRP-conjugated secondary antibody
Goat anti-Mouse at 1:1000 and developed by enhanced chemiluminescence (ECL, GE
Healthcare). As a load control anti-βActin conjugated with HRP was also assessed
after HRP-inactivation of the membranes. Band intensity was acquired using the UVI
Soft software (UVITEC, Cambridge). Finally, band intensities were quantified relatively
using ImageJ by densitometric analysis [135].
2.4 Biochemical Assays on PrPSc and PrPC
2.4.1 Proteinase-K (PK) digestion
The accumulation of PK-resistant PrP in cell lysates was detected by proteinase K (PK)
digestion followed by immunoblotting. For each sample, 500 µg of total protein, 20
µg/mL PK (Roche, ratio protein:PK = 50:1) and lysis buffer added to a final volume
of 0.5 mL was prepared. Samples were then incubated at 37◦C for one hour. The
reaction was stopped by adding PMSF at a 2 mM final concentration. PK digested
products were precipitated by centrifugation at 100,000 x g for 1 hour at 4◦C in an
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ultracentrifuge (Beckman Coulter) and resuspended in LB 2X. All samples were boiled
for 10min at 100◦C, then stored at -20◦C until analysis by immunoblotting.
2.4.2 Protein deglycosylation by Endo H or PNGase F
For the glycosidase assays, 30 µg total protein of cell lysates were treated with Endo H
or PNGase F enzymes (New England Biolabs), following manufacturer’s instructions.
Briefly, 1 µL of 10X glycoprotein denaturing buffer (provided with the kit) was added
to the cell lysates and the samples were boiled for 10 minutes at 100◦C. Samples were
chilled on ice and spun down. Next, for Endo H digestion, 2 µL 10X Glyco Buffer
3 and 1 µL of Endo H were mixed into the reaction; while for PNGase F digestion
2 µL Glyco Buffer 2 (10X), 2 µL 10% NP-40 and 1 µL of PNGase F were mixed in.
Samples were incubated overnight at 37◦C. Finally, LB 2X was added and samples were
boiled for 10 min at 100◦C to stop the reaction, then stored at -20◦C until analysis by
immunoblotting.
2.4.3 Solubility Assay
Cell lysates containing 100 µg of total protein was adjusted to a final volume of 500 µL
in lysis buffer containing PMSF (final concentration 2 mM). Samples were incubated on
ice for 20 min before centrifugation at 100,000 x g for 1 hour at 4◦C in an ultracentrifuge
(Beckman Coulter). The supernatant was recovered, collected by acetone precipitation
and resuspended in 50 µL TGS buffer for further analysis by immunoblot. The pellet
was washed twice by resuspension in 500 µL lysis buffer containing PMSF and recovered
by centrifugation at 100,000 x g for 1 hour at 4◦C in an ultracentrifuge (Beckman
Coulter). The pellet was resuspended in 50 µL TGS buffer for further analysis by
immunoblot.
2.5 Immunofluorescence
2.5.1 Immunofluorescence for the detection of PrP and
organelles
Cells were cultured on poly-L-lysine coated coverslips for 24 h. Medium was removed
and cells were fixed with 4% paraformaldehyde (PFA) in phosphate-buffered saline
(PBS) for 20 min at RT. Cells were washed 3X for 5 min with PBS then permeabilized
with 0.3% Triton X-100 in PBS for 10 min and subsequently blocked in 7% NGS in
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PBST (PBS 1X + 0.05% Triton X-100) for 1 hr at RT. After blocking, cells were
incubated in the primary antibody in 1% NGS in PBST in a humidified chamber O/N
at 4◦C. The next day coverslips were washed 4X with PBS 1X, incubated with the
secondary antibody conjugated with Alexa Fluor in 1% NGS in PBST for 1 hr at RT
in the dark, and washed 2X in PBS 1X. Finally, cells were incubated in DAPI (1:500)
in PBST for 15 min and washed a final time with PBS 1X. Coverslips were air dried
and mounted on coverslips using Vectashield (VECTOR Laboratories), allowed to dry,
sealed and stored in the dark at 4◦C.
2.5.2 Immunofluorescence for the surface staining of PrP
Cells were cultured on poly-L-lysine coated coverslips for 24 h. Cells were then placed
on ice for 20 min, after the medium was replaced with medium containing the primary
antibody for 30 min washed 1X in PBS 1X still on ice. Cells were fixed with 4%
paraformaldehyde (PFA) in PBS for 20 min at RT. Cells were washed 3X for 5 min
with PBS 1X then incubated with the secondary antibody conjugated with Alexa Fluor
in 1% NGS in PBS 1X for 1 hr at RT in the dark, and washed 2X in PBS 1X. Finally,
cells were incubated in DAPI (1:500) in PBST for 15 min and washed a final time
with PBS 1X. Coverslips were air dried and mounted on coverslips using Vectashield
(VECTOR Laboratories), allowed to dry, sealed and stored in the dark at 4◦C.
2.5.3 Antibodies used for immunofluorescence
The primary antibody used to detect PrP was W226 at 1:200. The organelle markers
primary antibodies, purchased from Abcam, were the ER marker (anti-Calnexin), the
early endosome marker (anti-EEA1), the recycling endosome (anti-Transferrin receptor
Tfn), the late endosome marker (anti-Mannose-6 phosphate receptor M6PR) and the
lysosome marker (anti-LAMP1), all used at 1:400. Secondary antibodies (used at 1:400)
were Alexa Fluor-488 goat anti-mouse for W226 and Alexa Fluor-594 goat anti-rabbit
for the organelle markers.
2.5.4 Image Acquisition
Images were acquired with a Nikon Eclipse Ti confocal microscope equipped with NIS
Elements Nikon Confocal Software.
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2.6 Preparation of scrapie cell seed by sodium
phosphotungstic acid (PTA)
1 mg of ScN2a or N2aPrP−/− cell lysate was used for PTA precipitation by adding
500 µL of PBS 1X containing 4% sarkosyl, PMSF (final concentration 2 mM) and 0.5%
PTA, with constant shaking 300 rpm, at 37◦C for 1 hour and centrifuged 14,000 g for
30 min at RT. The pellet was washed with 500 µL of PBS 1X containing 2% Sarkosyl
and PMSF (final concentration 2 mM) then centrifuged again at 14,000 g for 30 min
at RT. The pellet was washed a final time with 500 µL of PBS 1X and centrifuged a
final time at 14,000 g for 45 min at RT. After that, the supernatant was discarded and
the pellet was resuspended in 150 µL of PBS 1X and stored at -20◦C until use.
2.7 Preparation of recombinant proteins
2.7.1 Protein expression
Recombinant MoPrP(23-231) and MoPrP-H95E(23-231) were expressed and produced
in E. coli Rosetta DE3 bacteria grown in LB medium (10g tryptone, 5 g yeast extract,
10 g NaCl) as follows. Freshly transformed 100 mL overnight culture of Rosetta DE3
bacteria divided equally among 3 flasks of 750 mL each of LB medium plus ampicillin
(100 µg/mL). These were grown at 37◦C with vigorous shaking until the OD600 reached
0.5 at which point they were induced with IPTG (at 0.8mM), and grown O/N at 37◦C
with vigorous shaking. Cells were harvested by centrifugation at 4000 g, 4◦C for 30
min.
2.7.2 Isolation of inclusion bodies
The bacteria pellet was resuspended in 25 mM Tris-HCl, 5 mM EDTA, 0.8% Triton
X-100, 0.4% Deoxycholic acid, 1 mM PMSF, pH 8 and lysed by Panda Plus homogenizer
at 4◦C. Bacteria cells were disrupted by three cycles of mechanical lysis at 1500 bar.
Inclusion bodies (IBs) were collect by centrifugation at 10,000 g, 30 min, 4◦C, washed
once with washing buffer (25 mM Tris-HCl, 5 mM EDTA, 0.8 % Triton X-100, pH 8),
and then again with cold water twice. Washed IBs were solubilized in 5 volumes of 8
M GdnHCl, and then bacterial debris was removed by centrifugation at 10,000 g, 30
min, 4◦C.
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2.7.3 Protein purification
The dissolved IBs in 8 M GdnHCl were diluted to 6 M GdnHCl using 50 mM Tris, 1
M NaCl, pH 8.0 then loaded onto a 5mL HisTrap crude column (GE Healthcare) in
binding buffer (2 M GdnHCl, 500 mM NaCl, 20 mM Tris, 20 mM imidazole, pH 8.0).
After that, the column was washed with 3 column volumes of binding buffer and eluted
with a gradient from 0-100% of elution buffer (5 M GdnHCl, 500 mM NaCl, 20 mM
Tris, 500 mM imidazole, pH 8.0) at 5 mL/min in 20 min. Finally, the PrP-contained
fractions were loaded onto the gel filtration column (Superdex 200 26/60, GE) and
eluted with 6 M GdnHCl, 25 mM Tris-HCl, 5 mM EDTA, pH 8 at a flow rate of 2
mL/min. Purified protein was analyzed by SDS- PAGE and Coomassie staining. Protein
concentration was determined by UV at 280 nm and stored at -20◦C until use.
2.7.4 Protein refolding
Purified prion proteins were rapidly diluted to a final concentration of 0.1 mg/mL using
25 mM Tris, 5 mM EDTA, pH 8.0. Then the samples were dialyzed against refolding
buffer (20 mM NaOAc, 0.005% NaN3, pH 5.5) using a 3 kDa molecular weight cut-off
(MWCO) membrane (Spectra/Por), until a final GdnHCl concentration of about 10
µM.
2.8 Generation and detection of transgenic mice
MoPrP mutant transgenes (H95E) containing mouse regulatory sequences were excised
from the plasmid pJB::MoPrP(1-254, H95E) with the restriction endonuclease NotI.
These fragments were microinjected into the pronucleus of 200 fertilized FVB mice
eggs, which were implanted into pseudopregnant FVB females. This work was done at
the transgenic mouse facility of Cyagen Biosciences Inc (USA).
DNA collected from the tails of F0 offspring mice was used to screen for transgene
integration by a PCR assay using specific primers. The primers used were 5’-GAA
CTG AAC CAT TTC AAC CGA G-3’ and 5’-AGA GCT ACA GGT GGA TAA CC-3’.
The presence of PCR-amplified products of 800 bp indicated the presence of MoPrP
mutant transgenes. Transgenic F0 mice were crossed with WT mice to obtain an F1
generation that was also screened using PCR amplification as above. Unfortunately, no
F1 offspring containing the transgene were obtained. This work with transgenic mice
was performed in collaboration with the group of Prof. Juan-Maria Torres at Centro de
Investigacion en Sanidad Animal (CISA-INIA), Madrid, Spain.
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2.9 Statistical analysis
Western blot protein bands were relatively quantified by densitometry with ImageJ.
When possible (i.e. samples analyzed without PK digestion), PrP bands were normalized
to β-actin as an internal control of load control (total protein was also quantified by
BCA and equal amounts added to each well). Then PrP variable were analyzed as
a ratio of WT PrP levels. For experiments with transfection, an additional level of
calculation was necessary to account for the transfection efficiency of each sample. To
this aim we calculated the ratio of the PK digested protein band of the sample with
the anti-PrP 3F4 antibody with respect to the PK digested protein band PrP WT with
anti-PrP 3F4, then compared this to the ratio of the non-PK digested protein band of
the sample normalized to β-actin with respect to the non-PK digested PrP WT 3F4
within each gel.
For the experiments with CPZ, a similar approach was used, but we included an equal
external loading control in each gel as a reference to compare WT PrP levels between
gels to quantify the variance of WT PrP samples to avoid variance heterogeneity.
When applicable we used a one-way analysis of variance (one-way ANOVA), if differences
among means were found to be statistically significant, we performed the post hoc
multiple comparisons test with the mean of the WT group, using the Dunnett’s
multiple comparison to account for the family-wise error rate when performing multiple
comparisons. Each p-value is adjusted to account for multiple comparisons, with
family-wise significance, at 0.05.
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3 Chapter 3Results
3.1 Amino acid scanning of H95 reveals a ”hot
spot" for prion conversion
In previous work in our lab, five of the copper binding histidines from the OR and non-
OR regions were individually mutated to tyrosine, a conservative mutation that removes
the physiological copper binding ability. By analyzing the conversion susceptibility from
PrPC to PrPSc in vitro, they uncovered that only the mutation in the non-OR region,
H95Y, resulted in a significant increase in prion conversion propensity [73].
Intrigued with the H95 site, we wondered if other amino acid substitutions would have
similar effects on prion conversion. To this effect, we completed an amino acid scan of
H95, replacing the histidine with every other common amino acid and measuring the
prion conversion propensity. This was done with the prion conversion assay, a method
to quantify the conversion of PrPC to PrPSc. We transiently expressed our mutant PrPs
of interest into N2a cells chronically infected with RML prions (ScN2a). Fundamental
to this method, exogenous PrP that is transiently transfected into ScN2a cells can
convert into PrPSc. We transiently transfected ScN2a cells with our PrP mutants of
interest, collected the cell lysates 72 hours later and analyzed by PK digestion and
immunoblot. To discriminate between endogenous and exogenous PrP, the 3F4 tag,
a human-specific epitope with methionine substitutions at residues 108 and 111, was
added to all constructs and later detected by the 3F4 antibody [30] [1] [2] [3]. The
3F4 antibody was confirmed to be specific for 3F4-tagged PrP (Figure 3.1A). We
also confirmed that this tag does not influence endogenous protein expression or prion
conversion (Figure 3.1B).
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Figure 3.1: Anti-PrP 3F4 antibody is specific to the 3F4 epitope tag and does not
disrupt prion conversion. (A) PK digested and non-PK digested samples
were blotted first with anti-PrP 3F4, then stripped and blotted with anti-
PrP W226 Antibody. We detect no cross-reactivity with native mouse
PrP, seen here in the cells transfected with the empty vector, and specific
recognition of PrP containing the 3F4 epitope, as seen in lanes with PrP
WT3F4. (B) Western blot comparison of ScN2a cells without transient
transfection (Mock), expressing an empty vector (empty), expressing the
MoPrP construct (WT), or the MoPrP construct with the 3F4-tag (WT3F4).
No effect of 3F4-epitope tag on PrP expression and PK-resistance was
detected.
Western blot analysis of total PrP expression level (endogenous and exogenous) by
the W226 antibody revealed no differences either before or after PK digestion. The
expression level of exogenous PrP, as detected by the 3F4 antibody, showed similar PrP
expression levels among all constructs without PK digestion Figure 3.2 (A). Importantly,
after PK digestion, there are marked changes in the prion conversion propensity of the
constructs Figure 3.2. When H95 was substituted with a neutral or small amino acids
(A, G, C, S, T, N, Q, P), the PrPSc levels were comparable to WT. However, when H95
was replaced by hydrophobic amino acids (F, Y, L, M, V, W, I), the PrPSc levels were
dramatically increased. The cases of V, F, Y, and I had the highest increase of prion
conversion, with levels 2-3 times higher than WT. On the other extreme, substitutions
with the charged amino acid residues (D, E, K, R) had a low rate of PrPSc conversion,
suggesting that these substitutions somehow dissuade prion conversion.
These data suggest that the fifth copper binding site, H95, is a ”hot spot" for prion
conversion since by amino acid substitutions at this position, the prion conversion
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propensity is highly promoted or inhibited, possibly dependent on the hydrophobicity of
the substituting amino acid.
This amino acid scan was a preliminary screening with a sample size of 2. It has the
potential to be highly interesting, and as such, requires much study. In this work
we have focused on the charged side chains that decrease the conversion propensity,
doing extensive studies to confirm this preliminary result and shed some light on the
mechanisms involved behind these stunning findings.
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Figure 3.2: Effect of amino acid substitutions at H95 on prion conversion (A) Fifty µg
of undigested cell lysates from ScN2a cells expressing 3F4-tagged WT and
mutant PrPs were applied to each lane. Five hundred µg of cell lysates
were digested with PK at 37◦C for 1 hour. Exogenous 3F4-tagged PrP was
detected by the anti-PrP 3F4 antibody. B-actin was used as an internal
loading control. (B) Quantitative analysis of PK-resistance levels (PrPSc)
in transfected constructs.
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3.2 H95 substituted with amino acids containing
charged side chains reduces prion conversion in
vitro
To confirm the preliminary results of the amino acid scan in the mutants which decreased
prion conversion propensity, we again utilized the prion conversion assay.
The following constructs were used: MoPrP WT3F4, MoPrP H95D3F4, MoPrP H95E3F4,
MoPrP H95K3F4, MoPrP H95R3F4 (and additionally MoPrP H95Y3F4 as another control
of the experiment to compare with previous results) and an empty vector lacking PrP
and the 3F4 tag (hereby referred to as WT3F4, H95D3F4, H95E3F4, H95K3F4, H95R3F4,
H95Y3F4 and empty, respectively). ScN2a cell viability was not affected by transient
transfection of any of the constructs, indicating that the expression of PrP WT3F4 and
mutants had no toxic effect on ScN2a cells (Figure 3.3).
Figure 3.3: Mutant constructs transiently transfected into ScN2a cells do not decrease
cell viability, as tested with MTT assay. Quantitative analysis of the cell
viability percentage in transfected constructs relative to mock transfected
ScN2a cells (n=3).
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Analysis of the total PrP expression level (endogenous and exogenous) by the W226
antibody revealed no differences either before or after PK digestion, so transfection
with mutant PrP did not alter ScN2a cells’ ability to express PrP (Figure 3.4). Analysis
of exogenous PrP by the 3F4 antibody showed similar exogenous PrP expression
level among all constructs without PK digestion, as determined by one-way ANOVA
(F(5,24)=1.308, p=0.2936). Therefore, expression of the exogenous protein in the cell
was not affected by the mutant type (Figure 3.5A, 3.5B).
Importantly, after PK digestion, we were able to confirm the marked changes in the prion
conversion propensity of the constructs. In line with our preliminary, exploratory ex-
periment, compared to WT3F4 PrPSc, the mutants H95D3F4 (M=26.96%, SD=19.02%),
H95E3F4 (M=27.48%, SD=23.11%), H95K3F4 (M=34.74%, SD=10.70%), and H95R3F4
(M=65.19%, SD=22.42%) had reduced PrPSc and H95Y3F4 (M=348.5%, SD=132.2%)
increased PrPSc (Figure 3.5A, 3.5C). With this we contribute the first robust evidence
of these mutations’ ability to decrease prion conversion propensity.
A B
Figure 3.4: Total PrP expression level was similar in all ScN2a cells transiently trans-
fected with 3F4-tagged mutant PrPs for prion conversion assay experiments.
(A) PrP detected by anti-PrP W226 antibody without and with PK diges-
tion. β-actin was used as an internal loading control. (B) Quantitative
analysis of β-actin-normalized total PrP expression levels without and with
PK digestion (n=5).
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Figure 3.5: The H95 substitution with charged amino acids impedes prion conversion
and confirmation of H95Y increasing prion conversion. (A) Forty µg of
undigested cell lysates from ScN2a cells expressing 3F4-tagged WT and
mutant PrPs were applied to each lane. Five hundred µg of cell lysates
were digested with PK at 37◦C for 1 hour. Exogenous 3F4-tagged PrP was
detected by the anti-PrP 3F4 antibody. B-actin was used as an internal
loading control. (B) Quantitative analysis of non-PK digested expression
levels of exogenous mutant PrP compared to PrP WT3F4. (C) Quantitative
analysis of PrPSc PK-resistance levels in transfected constructs. PK resistant
mutant PrP is represented in the graph as a percent of PK digested PrP
WT3F4, with transfection efficiency (n=5).
For further studies we chose to focus the PrP mutation with the lowest prion conversion
propensity: H95E. Additionally, we used PrP WT as a control and continued to analyze
PrP H95Y as a positive control, consistently comparing these to appreciate any small
differences by comparing the WT and the two extremes of prion conversion.
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3.3 Chelation of copper slightly increased prion
conversion propensity in PrP H95E and WT PrP
WT PrP can coordinate up to six copper ions in the N-terminal, but the mutation at
H95 removes one of these copper binding sites. We investigated the effect general
depletion of copper would have on our system. To explore this we used the prion
conversion assay, described in Section 3.1, where we treated ScN2a cells transiently
transfected with WT3F4, H95D3F4, H95E3F4, H95K3F4 or H95R3F4 and treated the
cells with 10 µm of the copper chelator cuprizone (CPZ). After 48 of hours CPZ
treatment, PK-resistance levels were evaluated.
The CPZ treatments had no significant effects on the prion conversion propensity of any
of the transfected PrPs compared to the same transfected PrP without CPZ (Figure
3.6). We see again the basic trends noticed before, but the removal of copper from the
medium while not statistically significant, did show a trend of moderately increasing
prion conversion, especially in PrP H95E CPZ, with a 37.05% increase compared to
PrP H95E and PrP WT CPZ, with a 38.74% increase compared to PrP WT.
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Figure 3.6: Copper chelation moderately raised prion conversion propensity in PrP
H95E and WT PrP. (A) After transfection, ScN2a cells were treated with
10 µm CPZ for 48 hours. Forty µg of undigested cell lysates from ScN2a
cells expressing 3F4-tagged WT and mutant PrPs with or without CPZ
treatment were applied to each lane. Five hundred µg of cell lysates were
digested with PK at 37◦C for 1 hour. Exogenous 3F4-tagged PrP was
detected by the anti-PrP 3F4 antibody. B-actin was used as an internal
loading control. (B) Quantitative analysis of PrPSc PK-resistance levels in
transfected constructs with or without CPZ treatment PK resistant mutant
PrP is represented in the graph as a percent of PK digested WT PrP, with
transfection efficiency (n=4).
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3.4 Biochemical features of PrP H95E
3.4.1 Generation of stable cell lines expressing PrP WT and
H95 mutants from N2aPrP−/− cells.
To study the biochemical features of the H95E mutant, we created Geneticin-resistant
monoclonal stable cell lines from N2aPrP−/− cells: N2aPrP−/− WT, N2aPrP−/−
H95E, N2aPrP−/− H95Y. These cell lines do not contain the 3F4 tag and express only
PrP WT, with PrP reintroduced; or express PrP H95E or PrP H95Y, each of which
only differ from PrP WT by this single amino acid. The expression of the mutant PrP
was not toxic to the cells, indicating that genomic expression of WT PrP, PrP H95E or
PrP H95Y do not have a toxic effect on N2a−/− cells (Figure 3.7B). One clone of
each condition which expressed PrP at levels closest to those found in N2a cells was
selected for further experiments (Figure 3.7A).
A B
Figure 3.7: Expression of PrP in N2aPrP−/− cells. (A) Forty µg of cell lysates were
loaded into each lane and PrP was detected with anti-PrP W226 antibody.
β-actin was used as an internal loading control. (B) MTT assay of stably
transfected cell lines: N2a PrP−/− H95E, N2a PrP−/− H95Y, N2a
PrP−/− WT, showed no decrease in cell viability compared to N2a−/−
cells (n=3).
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3.4.2 PrP H95E shares similar glycosylation patterns with PrP
WT
To further determine if the prion conversion propensity differences observed could be
explained by altered maturation processes, we studied the innate glycosylation patterns
and those resulting from glycosidase digestion. Western blot analysis showed that PrP
H95E, PrP H95Y and PrP WT all share the same glycosylation patterns, migrating
with the classical three bands composed of the diglycosylated, monoglycosylated and
unglycosylated PrP (Figure 3.8B, untreated lanes).
Next, to monitor proper processing of the posttranslational addition of N-linked oligosac-
charide chains and PrP translocation from the ER to the Golgi (explained in detail
in Section 1.2.2) of PrP H95E, PrP H95Y and PrP WT, we treated cell lysates to
Endo H or PNGase F digestion. Endo H sensitivity is a sign of an immature protein
that has not been properly processed through the Golgi [4]. PNGase F will cleave all
N-linked oligosaccharide chains from PrP. We found that all of our cases (PrP H95E,
PrP H95Y and PrP WT) were resistant to Endo H digestion and showed no differences
between them (Figure 3.8A). Also, treatment with PNGase F in all cases resulted in
two bands, the unglycosylated full length PrP (fl) and the C1 fragment of PrP (C1)
(Figure 3.8B). There were no statistically significant differences between the means
of the proportions of C1:fl between the cell lines as determined by one-way ANOVA
(F(3,12)=0.628, p=0.61) (Figure 3.8C).
Together these data indicate that these mutant proteins are successfully processed
through the ER and Golgi compartments resulting in mature PrP. Additionally, the
presence of the C1 fragment after PNGase F digestion at equal levels compared to N2a
cells indicates that α-cleavage processing is not affected by the amino acid substitutions
or the introduction of the transgene into the genome.
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Figure 3.8: The H95 mutants share the same glycosylation patterns and proteolytic
characteristics with PrP WT. (A) Thirty µg of either undigested cell lysates
or digested with Endo H or (B) PNGase F. The full length PrP (fl) and
C1 fragment (C1) are indicated. The positions of the diglycosylated (di),
monoglycosylated (mono) and unglycosylated forms can be appreciated in
the untreated lanes. PrP was detected by anti-PrP W226 antibody and
B-actin was used as an internal loading control. (C) Quantitative analysis
of the ratio of C1:fl after PNGase F digestion. n=4
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3.4.3 Glycosidase digestion of ScN2a cells transiently
transfected with PrP mutants with PNGase F revealed
no differences of de-glycosylated patterns
We also digested samples of ScN2a cells transiently transfected with PrP WT3F4, PrP
H95E3F4 and PrP H95Y3F4 with PNGase F to compare the ratio of C1:C2 fragments,
where an increase of C2 fragments is linked to prion disease. Unfortunately, the process
of α-cleavage destroys the 3F4 epitope, so exogenous C1 fragments could not be
visualized. We notice that the ratio of C2 fragment to full length protein is about 1:1
in all three cases (Figure 3.9).
Figure 3.9: The H95 mutants transiently expressed in ScN2a cells share the same
glycosylation patterns and proteolytic characteristics with PrP WT. Thirty
µg of cell lysates from transiently transfected ScN2a were either undigested
or digested by PNGase F were applied to each lane. The full length PrP (fl),
C1 fragment (C1), and C2 fragment (C2) are indicated. The positions of
the diglycosylated (di), monoglycosylated (mono) and unglycosylated forms
can be appreciated in the untreated lanes. PrP was detected by anti-PrP
W226 antibody for total PrP and anti-PrP 3F4 for exogenous, mutant PrP.
B-actin was used as an internal loading control.
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3.4.4 Solubility of PrP H95E and H95Y are unchanged
Solubility is an important biochemical property that differs between PrPSc and PrPC.
Soluble and insoluble PrP were separated by centrifugation at high speed. The resulting
supernatant (soluble proteins) and pellet (insoluble proteins) were analyzed by Western
Blot (Figure 3.10A). As expected, PrP of ScN2a cells contained a high amount of
insoluble PrP (M=60.40%, SD=10.13). The rest of the cell lines examined contained
roughly 20% insoluble PrP. PrP H95E and H95Y show slightly increased insolubility
compared to WT, but very marginal (Figure 3.10B).
A
B
Figure 3.10: Solubility of mutant PrPs is slightly decreased. (A) Cell lysates from
N2a PrP−/− cells stably expressing PrP WT, PrP H95E and PrP H95Y
were separated into supernatant (S) and pellet (P) fractions by 100,000
x g ultracentrifugation and subsequent washes. PrPs were detected by
anti-PrP W226 antibody. (B) olubility profile for PrP of each cell line,
percentage of insoluble PrP determined by the relative densitometry of
the pellet signal relative to the total of the pellet and supernatant signal
(n=4).
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3.5 Localization and trafficking in N2aPrP−/−
H95E, N2aPrP−/− H95Y cells
PrP WT, H95E and H95Y were stably expressed in N2a−/− cells and visualized
by immunofluorescence to determine the localization of the WT and mutant PrPs.
Compared to N2a cells endogenously expressing PrP, N2a−/− cell lines expressing WT,
H95E and H95Y all had similar PrP distribution and localization: predominantly at the
cell surface (Figure 3.11) with some intracellular localization as seen by the combined
cell surface and intracellular staining of PrP in Figure 3.12.
Figure 3.11: H95E and H95Y mutants are predominantly expressed on the cell surface,
like WT PrP. Cell surface staining of N2a cells and stable transfection of
PrP WT, H95E and H95Y in N2aKO cells. PrP on the cell surface was
detected by anti-PrP W226 without permeabilization. PrP is in green,
DAPI nuclear staining in blue, with merged images. Scale bar: 10 µm.
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To further explore the subcellular localization and trafficking of PrP H95E and PrP
H95Y, we analyzed the localization patterns of our mutants with respect to several
organelle markers (Figure 3.12). All four of our cell lines analyzed, N2a, N2a−/−
PrP WT, N2a−/− PrP H95E and N2a−/− PrP H95Y continued to show prp mainly
expressed at the cell surface. In the N2a and N2a−/− PrP WT cell lines, prp localizes
with EEA1 (early endosomal marker), Tfn (endosomal recycling compartment marker),
LAMP1 (lysosomal marker); while there was no specific localization with M6PR (late
endosome marker) or Calnexin (ER marker). Our mutant cell lines N2a−/− PrP
H95E and N2a−/− PrP H95Y shared the same localization patterns as PrP WT in
reference to the organelle markers, except for localization with the endosomal recycling
compartment marker (Tfn). The WT PrP (of both N2a cells and N2a−/− WT PrP)
localize with Tfn as does PrP H95Y, though at a higher extent than WT PrP. However
PrP H95E does not localize with Tfn. This difference of association with the endosomal
recycling compartment marker, could affect the likelihood of PrP to misfold into PrPSc,
as these mildly acidic compartments have been proposed as a likely site for prion
conversion [129] [133] and pH has been found to have an effect on prion conversion
propensity of PrP [73] [134].
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Figure 3.12: The H95E and H95Y mutants display altered localization patterns in the
endosomal recycling compartments. (A) PrP localization in N2a cells (B),
N2a PrP−/− WT PrP (C), N2a PrP−/− H95E (D) and N2a PrP−/−
H95Y with reference to organelle markers. PrPs are detected by anti-PrP
W226 antibody (green), nuclei are labeled with DAPI (blue) and organelle
markers (red): Calnexin (ER marker), EEA1 (early endosome marker),
Tfn (endosomal recycling compartment marker), M6PR (late endosome
marker) and LAMP1 (lysosome marker). Insets show a magnification of
the merged panels from white boxed areas. Scale bar: 10 µm.
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3.6 Attempted establishment of Tg mice expressing
MoPrP H95E
We used pJB1, a modified from MoPrP.Xho, as the vector to carry MoPrP H95E. This
vector provides relatively high levels of transgene-encoded proteins in the brains and
hearts of Tg Mice [5]. The MoPrP H95E coding sequence was inserted into pJB1,
resulting in pJB::MoPrP(1-254, H95E). At the transgenic mouse facility of Cyagen
Biosciences Inc (USA), the H95E mutant transgenes containing mouse regulatory
sequences were excised from the plasmid and microinjected into the pronucleus of
fertilized FVB mice eggs. Mice with transgene integration were screened by PCR using
specific primers. Three F0 mice containing the transgene were identified and shipped
to the animal facilities of Prof. Juan Maria Torres, INIA, Madrid, Spain. Here the mice
were crossed with WT mice to obtain an F1 generation that was also screened using
PCR amplification as above. Unfortunately, no F1 offspring containing the transgene
were obtained (Figure 3.13).
A B
Figure 3.13: PCR assay for Tg mice screening. (A) PCR assay identifying three founders.
Transgene PCR product size is 800 bp, internal control PCR product size
is 515 bp. Positive control is 400 ng of mouse genomic DNA spikes with
transgene injection DNA equal to 5 copies of transgene per diploid mouse
genome. WT control is 400 ng of mouse genomic DNA. Water control is
no DNA template added. (B) Representative PCR assay screening F1 mice.
Transgene PCR product size is 800 bp. None of the progeny contained
the transgene.
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3.7 Expression and purification of recombinant PrP
MoPrP23-231 WT and MoPrP23-231 H95E were cloned into pET11a. These recom-
binant proteins were produced in E. coli Rosetta DE3 in LB medium. We show the
results of MoPrP23-231 H95E here as a reference.
After induction with IPTG, MoPrP23-231 H95E was overexpressed in bacterial cells
with clear band in SDS-PAGE (Figure 3.14A). MoPrP23-231 H95E was expressed
in the bacteria as insoluble inclusion bodies, therefore they had to be solublized in
8M GdnHCl and purified under denaturing conditions. MoPrP23-231 H95E contains
multiple Histidine regions in the N-terminal that can bind metals, such as copper,
nickel and zinc. Relying on this characteristic, we first purified MoPrP23-231 H95E
by Immobilized metal ion affinity chromatography (IMAC) by Histrap column. After
this first purification, proteins were quite pure, with only a few contaminant bands.
A second purification step of size exclusion chromatography (SEC) was performed to
obtain highly purified proteins (Figure 3.14B). Protein purity and identity was confirmed
by Ponceau stain and by Western blot with the W226 antibody (Figure 3.14C & 3.14D).
These proteins will be used to analyze the kinetics of MoPrP23-231 H95E compared to
MoPrP23-231 WT in fibrillization assay and RT-QuIC.
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Figure 3.14: Expression and purification of MoPrP23-231 H95E. (A) Expression of
MoPrP23-231 H95E in Rosetta DE3 bacteria before induction (t=0) and
16 hours after induction (t=16). (B) Purification of MoPrP23-231 H95E
by Histrap column. (C) WB analysis of recombinant protein purity by
Ponceau stain (D) and with anti-PrP W226 of both MoPrP23-231 WT
and MoPrP23-231 H95E.
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4 Chapter 4Discussion
Prion diseases represent a poorly understood strain of neurodegenerative diseases
with devastating effects to the brain. Understanding restraints and triggers of prion
conversion, the predominant event of prion diseases leading to the propagation and
infectivity of PrPSc, is crucial. Copper binding to PrP on the N-terminal,implicated in
prion disease and conversion, might represent a key factor for such diseases.
4.1 Amino acid substitution H95 vastly changes
prion conversion propensity
Previous work from our lab identified the non-OR histidine, the fifth of six copper
binding histidines on PrP, as influential on prion conversion propensity, a fact observed
when this histidine was substituted by the conservative mutation to tyrosine [73]. This
study was the first to highlight the importance of this site in the conversion process.
My colleagues reasoned from their work that it was most likely the absence of copper
coordination at H95 that made PrPC more susceptible to convert into PrPSc in acidic
conditions.
Prompted by these results, we performed an amino acid scan at H95, replacing histidine
with every other common amino acid. Remarkably, prion conversion propensity was
vastly changed depending on the amino acid substitution at the site. The residues with
hydrophobic side chains (V, F, Y, I, M, W, L) increased the prion conversion propensity,
while the electrically charged side chains (D, E, K, R) decreased the prion conversion
propensity.
As all of the substitutions removed the copper coordination ability at residue 95, but
the prion conversion propensity increased, decreased or stayed the same, it is clear that
simply the loss of copper binding at this site does not increase the protein’s likelihood
to convert to PrPSc.
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4.2 Charged amino acids at H95 decrease prion
conversion
We confirmed the previous results with substitutions that make PrPC less susceptible to
PrPSc conversion. Notably, all the amino acids changes which decrease prion conversion
propensity are charged amino acids: both negative (glutamic acid and aspartic acid) and
positive (arginine and lysine) (interestingly enough the final positively charged amino
acid, histidine, is the native amino acid for this residue, though with a pKa of 6.7, it is
often uncharged in physiological conditions). So, whereas one possible interpretation is
that Giachin et al. are still correct overall in their findings, copper might not per se be
the deciding factor, but rather the presence of a charge at this site which stabilizes the
structure against conversion.
When a hydrophobic side chain is placed at this site the opposite effect is instead
achieved. Hydrophobic side chains could increase the protein’s likelihood to aggregate.
The evidence for this is supported by the fact that due to thermodynamic pressure,
hydrophobic aggregation can occur between two different polypeptide chains if two
locally hydrophobic regions come into close contact in aqueous solution, forming amyloid
fibrils and insoluble aggregates [91].As such when a charged side chain is present, the
steric hindrance acts to hold the structure of this region in place, similarly to (or better
than) copper coordination.
It would be interesting to develop other mutants of PrP based on these findings
and observations, including the mutation of the other Histidine of the non-OR, both
Histidines of the non-OR and/or mutating all of the histidines of the non-OR and
OR region to glutamic acid (or another of the charged amino acids) to see the effect
on prion conversion propensity. My findings and observations incline me to predict
that mutating the other histidine of the non-OR region (residue H110) would have
a similar effect on prion conversion propensity as the mutant at H95. However, this
mutant might prevent the α cleavage processing of PrP, which could encourage more
β-cleavage. Increased β-cleavage is linked to prion diseases so it’s favoring could push
the system to increased PrPSc production, regardless of the substituting amino acid.
Mutating both of the non-OR histidines to glutamic acid would also likely still reduce
prion conversion potential structurally, but again α cleavage could be impaired, and
with no copper binding abilities in the non-OR, functional properties of this mutant
could be even more impaired. Finally, changing all of the histidines of the OR and
non-OR region to glutamic acid would likely still reduce the protein’s ability to convert
to PrPSc, but not significantly. However, I would predict that it would be toxic to
cell cultures as observed in in vivo studies removing all the copper-binding regions of
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the N-terminal [88]. In the same manner, I would expect it to severely disrupt many
physiological activities of PrPC , specifically those which require copper binding ability.
It might be the case that our mutant does not have so many negative effects on PrP
copper-related function given that copper can still bind to the non-OR region via H110,
and as such it would be interesting to test with some of the functions proposed for
PrPC .
4.3 Copper chelation mildly increases prion
conversion propensity
We found that the removal of copper from the medium by cuprizone (CPZ) tended
to increase the prion conversion propensity of PrP H95E3F4 and PrP WT3F4, but not
significantly. This is in line with previous work in our lab [73], though they found a
significant increase in prion conversion propensity in PrP WT3F4 when CPZ was added
to the medium at the same concentration, in the same assay and the same cell line.
The one change we could determine between the two experiments was the brand of fetal
bovine serum (FBS) used and we reason that this might account for the differences
seen. This highlights how delicate the influence of copper is on the prion conversion
process and how copper studies involving PrP have been so conflicting to date, as even
small changes in the system might have large implications on the results.
4.4 PrP H95E and PrP H95Y mutants behave
biochemically very similar to PrP WT
α and β-cleavage processing in PrP H95E and PrP H95Y continues at levels similar to
PrP WT. This makes it unlikely that an increase or decrease of PrP processing is the
cause of differing levels of prion conversion. We showed that PrP H95E and PrP H95Y
follow normal maturation through the ER and Golgi with glycosidase assays and are
expressed at the cell surface at levels comparable to WT PrP. From the cell surface
the mutant can be endocytosed to early endosomal compartments, but the fate of the
mutant PrPs after this point could differ.
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4.4.1 Potential role of the endosomal recycling compartment
in mutant PrP conversion
We studied the localization of PrP H95E and PrP H95Y compared to WT PrP using
immunofluorescence to mark various organelles. We found no differences between
the localization characteristics of the mutant and WT PrPs with respect to EEA1
(early endosomal marker), LAMP1 (lysosomal marker), M6PR (late endosome marker)
and Calnexin (ER marker). We did observe differences of localization patterns of
PrPs compared to Tfn (endosomal recycling compartment marker), where PrP WT
co-localizes, PrP H95Y co-localizes very strongly and PrP H95E does not co-localize
with the endosomal recycling compartment (ERC). Therefore, it seems that the degree
of PrP co-localization with the ERC is directly proportional to the prion conversion
propensity of the PrP. This is supported by another work that found that PrP sorting
to the endosomal recycling compartment is required for PrPSc production [129].
It would be interesting to test if blocking the movement of PrP from the early endosomes
to the ERC in PrP H95Y and PrP H95E cells would cause a decrease in prion conversion.
Of note, this method (overexpressing Rab22a) does not block early endosome to ERC
trafficking in N2a cells, these experiments would need to be performed in GT1 cells.
Results from this experiment could determine if the prion conversion propensity of PrP
is more dependent on structure, to the intracellular compartments it is trafficked to or
a combination of both.
Conflictingly, other work has showed that PrP internalization is not a requirement
for prion conversion [50]. However, these data do not exclude a role for intracellular
compartments in prion conversion, which may accelerate or spread the conversion and
propagation of PrPSc after its initial conversion at the cell surface.
It is interesting to consider how the ERC might promote prion conversion. It has been
suggested that the ERC allows for the close contact of many PrPs in a small space,
accommodating conversion [129]. Or the slightly acidic environment of the ERCs (pH
6.4-6.5) [132] could favor a structural change of PrP since it has been shown that the
mutant PrP H95Y is less stable than WT PrP at acidic conditions [73].
4.4.2 PK sensitive and infectious PrPSc
At this point we cannot rule out that the PrP H95E mutant produces PK-sensitive
PrPSc. To understand this we are performing RT-QuIC and amyloid seeding assays.
These assays will show if PrP H95E can convert into PrPSc in native conditions and
denatured conditions, respectively, even if it is PK-sensitive. However, even if it can form
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PrPSc in these assays, we cannot know if PrPSc of H95E is infective or disease-inducing.
To answer these final questions we can first test in vitro using de novo scrapie infection
assays in stably transfected N2a-/- PrP H95E cell lines. However, further in vivo
experiments are necessary with Tg mice expressing PrP H95E to have a more complete
picture of the possible infectious nature of PrP H95E.
We predict that mice expressing only the PrP H95E mutant would not show detrimental
phenotypes since Tg mice expressing PrP H95Y [unpublished data, Legname lab] do not
and our biochemical assays show similar behaviours of these two mutants. Also, due to
the decreased prion conversion propensity observed in the prion conversion assays, we
would expect that Tg mice expressing PrP H95E would not develop spontaneous prion
disease and after scrapie inoculation would have lengthened survival times compared to
WT mice.
4.4.3 Potential natural mutation of PrP H96Y in a human
patient
When we began work on the H96 site H96 site (human numbering; mouse equivalent
H95), we believed this to be a completely artificial mutation, however, we have found
that a patient from Spain carried the PrP H96Y mutation and likely died of prion
disease [28]. Unfortunately, an autopsy was not performed on this patient, so there is
no confirmation of the diagnosis. Also, as far as we are aware, it is the only reported
case of a natural mutation at this site. More information would be needed for any
conclusions to be drawn, but it is tempting to fit this with our experimental data, where
we find in in vitro and in in vivo mice experiments that this mutation causes an increase
in PrPSc formation.
4.5 Future directions for this project
Currently we are performing RT-QuIC and amyloid seeding assays to determine the
in vitro protein kinetics of PrP H95E compared to PrP WT. We are also finishing
the de novo scrapie infections of stably transfected N2a-/- PrP H95E cell lines. Next,
in vivo experiments are crucial and indispensable in order to asses the validity of the
results of in vitro experiments. The information extracted from in vivo experiments is
fundamental to support the relevance in live animals, a much more complicated system
than in vitro systems can replicate. The H95E mice generated did not transmit the
transgene to their offspring. We cannot explain why this occurred as we have no reason
to infer that PrP H95E would be toxic. Tg mice expressing PrP H95Y survive and
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transmit the transgene as expected. Structural studies by XFAS on PrP H95E would
be very interesting as they might shed light into the conformational properties that
play a role in the conversion process. In line with the results obtained by my colleagues
on the H95Y mutant, we would likely find that the PrP H95E mutant maintains the
more stable conformation in both acidic and physiological conditions, even though it is
unable to coordinate copper at residue 95.
4.6 Conclusions
These data reaffirm the hypothesis that the non-OR region of PrP is involved in prion
conversion, but now we can add that it is involved in both increased and decreased
prion conversion propensities.
The opportunity of finding the key mutations in PrP that might lead to a controlled tool
for prion disease sequestering is now bigger than ever. The continuous detailed studies
performed by my colleagues and I at Legname’s lab are a strong indication of fruitful
and possibly game-changing research in the prion field. The discovery of mutants, such
as the ones presented in this thesis, which might prove reduced conversion propensity
into PrPSc is an exciting path to pursue. If the confirmation of these results in vivo,
with zero or minimal negative effects on physiological function are confirmed, then the
usability of this to create prion-resistant animals would represent a unique possibility.
The research presented here will help us understand in a deeper way the mechanisms
involved in prion conversion and the players involved in such a delicate and poorly
understood process, which is a key element in prion diseases.
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